Stürup Anne Emilie, Hjorthøj Carsten, Albert Nikolai, Dolmer Signe, Birk Merete, Ebdrup Bjørn H, Eplov Lene Falgaard, Jensen Heidi, Vernal Ditte Lammers, Speyer Helene, Mors Ole, Nordentoft Merete
Copenhagen Research Center for Mental Health (CORE), Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Section of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Front Psychiatry. 2022 Jul 22;13:910703. doi: 10.3389/fpsyt.2022.910703. eCollection 2022.
Evidence is insufficient regarding the consequences of discontinuing vs. maintaining antipsychotic medication in patients with first-episode schizophrenia. Our aim was to examine tapered discontinuation vs. maintenance treatment regarding remission of psychotic symptoms and impact on other areas.
Patients included had a diagnosis of schizophrenia, were treated with antipsychotic medication, and were in remission of psychotic symptoms. Participants were randomized to tapered discontinuation or maintenance treatment with antipsychotic medication. Assessments were undertaken at baseline and after 1-year. The primary outcome was remission of psychotic symptoms without antipsychotic medication.
The trial was terminated due to insufficient recruitment. In total, 29 participants were included: 14 in the tapering/discontinuation group and 15 in the maintenance group. Adherence to maintenance treatment was poor. At 1-year follow-up, remission of psychotic symptoms without antipsychotic medication for 3 months was observed in five participants in the tapering/discontinuation group and two in the maintenance group.
Due to insufficient recruitment this study does not provide a conclusion on whether unfavorable outcomes or advantages follow tapering of antipsychotic medication. Recruitment and adherence to maintenance treatment encountered obstacles. Based on experiences from this trial, we discussed alternative study designs as consistent evidence is still needed on whether to continue or discontinue antipsychotic medication in remitted patients with first-episode schizophrenia.
https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000565-23/DK, EU Clinical Trials Register-EudraCT no. 2016-000565-23.
关于首发精神分裂症患者停用与维持抗精神病药物治疗的后果,证据尚不充分。我们的目的是研究逐渐停药与维持治疗对精神病性症状缓解及其他方面的影响。
纳入的患者被诊断为精神分裂症,正在接受抗精神病药物治疗,且精神病性症状已缓解。参与者被随机分为逐渐停药组或抗精神病药物维持治疗组。在基线和1年后进行评估。主要结局是在未使用抗精神病药物的情况下精神病性症状的缓解。
由于招募不足,该试验提前终止。总共纳入了29名参与者:逐渐停药/停药组14名,维持治疗组15名。维持治疗的依从性较差。在1年随访时,逐渐停药/停药组有5名参与者、维持治疗组有2名参与者在未使用抗精神病药物的情况下精神病性症状缓解达3个月。
由于招募不足,本研究未就抗精神病药物逐渐减量后是否会出现不良结局或优势得出结论。招募和维持治疗的依从性遇到了障碍。基于该试验的经验,我们讨论了替代研究设计,因为对于首发精神分裂症缓解期患者是否继续或停用抗精神病药物仍需要一致的证据。